How do we choose between atypical antipsychotics? The advantages of amisulpride

International Journal of Neuropsychopharmacology

Volumn 7, Issue SUPPL. 1, 2004, Pages

  Mortimer, Ann M ^a  

^a UNIVERSITY OF HULL   (United Kingdom)

Author keywords

Amisulpride; Atypical antipsychotics; Schizophrenia

Indexed keywords

AMISULPRIDE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 3 RECEPTOR; DOPAMINE 3 RECEPTOR BLOCKING AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SEROTONIN 2A RECEPTOR; ZIPRASIDONE;

AGITATION; AMENORRHEA; ANXIETY; CLINICAL TRIAL; CONFERENCE PAPER; DEPRESSION; DIZZINESS; DRUG CHOICE; DRUG COST; DRUG EFFICACY; DRUG TOLERABILITY; EJACULATION DISORDER; EXTRAPYRAMIDAL SYMPTOM; GASTROINTESTINAL SYMPTOM; GLUCOSE TOLERANCE; HEART DISEASE; HUMAN; HYPERPROLACTINEMIA; HYPERSALIVATION; IMPOTENCE; INSOMNIA; MASTALGIA; NEGATIVE SYNDROME; NEUTROPENIA; ORTHOSTATIC HYPOTENSION; POSITIVE SYNDROME; PRIORITY JOURNAL; PSYCHOSIS; RECEPTOR AFFINITY; SCHIZOPHRENIA; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; TACHYCARDIA; WEIGHT GAIN;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS; DOPAMINE ANTAGONISTS; HUMANS; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SULPIRIDE; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 1842471069     PISSN: 14611457     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1461145704004134     Document Type: Conference Paper

References (13)

1. Boyer P, Lecrubier Y, Puech AJ, Dewailly J, Aubin F (1995). Treatment of negative symptoms in schizophrenia with amisulpride. British Journal of Psychiatry 166, 68-72.
2. Danion JM, Rein W, Fleurot O (1999). Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Amisulpride Study Group. American Journal of Psychiatry 156, 610-616.
3. Davis R, Markham A (1997). Ziprasidone. CNS Drugs 8, 153-159.
4. Davis JM, Chen N, Glick ID (2003). A meta-analysis of the efficacy of second-generation antipsychotics. Archives of General Psychiatry 60(6), 553-564.
5. Kapur S, Seeman P (2001). Does fast dissociation from the dopamine D(2) receptor explain the action of atypical antipsychotics?: a new hypothesis. American Journal of Psychiatry 158, 360-369.
6. Loo H, Poirier-Littre MF, Theron M, Rein W, Fleurot O (1997). Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia. British Journal of Psychiatry 170, 18-22.
7. Martin S, Ljo H, Peuskens J, Thirumalai S, Giudicelli A, Fleurot O, Rein W, SOLIANOL Study Group (2002). A double-blind, randomised comparative trial of amisulpride versus olanzapine in the treatment of schizophrenia: short-term results at two months. Current Medical Research and Opinion 18, 355-362.
8. Munro J, O'Sullivan D, Andrews C, Arana A, Mortimer A, Kerwin R (1999). Active monitoring of 12,760 clozapine recipients in the UK and Ireland. Beyond pharmacovigilance. British Journal of Psychiatry 175, 576-580.
9. National Institute for Clinical Excellence (NICE) (2002). Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia. Technology Appraisal Guidance - No. 43.
10. Paillere-Martinot ML, Lecrubier Y, Martinot JL, Aubin F (1995). Improvement of some schizophrenic deficit symptoms with low doses of amisulpride. American Journal of Psychiatry 152, 130-134.
11. Peretti CS, Danion JM, Kauffmann-Muller F, Grange D, Patat A, Rosenzweig P (1997). Effects of haloperidol and amisulpride on motor and cognitive skill learning in healthy volunteers. Psychopharmacology (Berlin) 131, 329-338.
12. Sechter D, Peuskens J, Fleurot O, Rein W, Lecrubier Y, Amisulpride Study Group (2002). Amisulpride vs. risperidone in chronic schizophrenia: results of a 6-month double-blind study. Neuropsychopharmacology 27, 1071-1081.
13. Tarsy D, Baldessarini RJ, Tarazi FI (2002). Effects of newer antipsychotics on extrapyramidal function. CNS Drugs 16, 23-45.